Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC007 in patients with post-COVID syndrome
2022-001781-35Phase 2Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Jan 2023
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ARC183 in post-COVID syndrome (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Treatment-emergent adverse events (TEAE). Started Jan 2023; status: completed.
02
Drugs
ARC183
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2022-001781-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001781-35.